Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Parcel Service
UPS
|
+$428M |
| 2 |
DexCom
DXCM
|
+$384M |
| 3 |
WIX.com
WIX
|
+$359M |
| 4 |
FTCH
Farfetch Limited Class A Ordinary Shares
FTCH
|
+$254M |
| 5 |
Caesars Entertainment
CZR
|
+$246M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.14B |
| 2 |
Microchip Technology
MCHP
|
+$535M |
| 3 |
Merck
MRK
|
+$512M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$444M |
| 5 |
Illumina
ILMN
|
+$413M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.59% |
| 2 | Healthcare | 18.35% |
| 3 | Consumer Discretionary | 11.3% |
| 4 | Financials | 10.45% |
| 5 | Communication Services | 9.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
Vanguard FTSE Europe ETF
VGK
$30.2B
| $40.1M | 0.02% |
596,729
+57,631
| +11% | +$3.89M |
|
627
Diodes
DIOD
$3.69B
| $39.9M | 0.02% |
500,080
+293,852
| +142% | +$22.6M |
|
|
HOLX
628
DELISTED
Hologic
HOLX
| $39.8M | 0.02% |
596,918
-310,686
| -34% | -$20.8M |
|
629
Biomea Fusion
BMEA
$90.4M
| $39.6M | 0.02% |
+2,627,382
| New | +$46.4M |
|
630
Levi Strauss
LEVI
$9.8B
| $39.4M | 0.02% |
1,421,107
-1,095,794
| -44% | -$30.1M |
|
631
Prudential Financial
PRU
$43B
| $39.3M | 0.02% |
383,998
+292,157
| +318% | +$29.8M |
|
632
Robert Half
RHI
$4.04B
| $39.1M | 0.02% |
440,029
-70,299
| -14% | -$6.13M |
|
|
ARGO
633
DELISTED
Argo Group International Holdings, Ltd.
ARGO
| $38.7M | 0.02% |
747,419
-78,675
| -10% | -$4.24M |
|
634
NetApp
NTAP
$34.2B
| $38.7M | 0.02% |
472,827
+407,070
| +619% | +$31.8M |
|
635
Western Digital
WDC
$160B
| $38.6M | 0.02% |
717,429
+169,121
| +31% | +$9.15M |
|
636
Kornit Digital
KRNT
$708M
| $38.3M | 0.02% |
307,692
-10,809
| -3% | -$1.14M |
|
637
Delek US
DK
$3.85B
| $38M | 0.02% |
1,759,278
-179,335
| -9% | -$4.05M |
|
638
Janus International
JBI
$732M
| $38M | 0.02% |
+2,689,173
| New | +$37.1M |
|
|
CYT
639
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $37.9M | 0.02% |
+1,889,833
| New | +$35.4M |
|
640
State Street
STT
$50.2B
| $37.8M | 0.02% |
459,634
+362,902
| +375% | +$30.6M |
|
641
Steven Madden
SHOO
$3.22B
| $37.7M | 0.02% |
862,264
-1,065,799
| -55% | -$44M |
|
642
FirstService
FSV
$6.58B
| $37.6M | 0.02% |
219,677
-8,230
| -4% | -$1.35M |
|
643
Franklin FTSE United Kingdom ETF
FLGB
$900M
| $37.6M | 0.02% |
1,518,186
+165,533
| +12% | +$4.18M |
|
644
Pfizer
PFE
$144B
| $37.5M | 0.02% |
958,276
-3,286,278
| -77% | -$128M |
|
|
DEA
645
Easterly Government Properties
DEA
$1.17B
| $37.5M | 0.02% |
711,462
-91,342
| -11% | -$4.83M |
|
646
Stride
LRN
$4.08B
| $37.5M | 0.02% |
1,165,658
-54,221
| -4% | -$1.62M |
|
647
4D Molecular Therapeutics
FDMT
$515M
| $37.1M | 0.02% |
1,539,726
+312,329
| +25% | +$9.56M |
|
|
LENZ
648
LENZ Therapeutics
LENZ
$184M
| $36.7M | 0.02% |
+178,715
| New | +$31.1M |
|
649
Edgewise Therapeutics
EWTX
$4.34B
| $36.7M | 0.02% |
1,789,280
-351,628
| -16% | -$9.61M |
|
650
Leidos
LDOS
$14.9B
| $36.4M | 0.02% |
360,153
-784,211
| -69% | -$80.5M |
|
Similar funds
Janus Henderson Group's Q2 2021 Portfolio in Review
As of Q2 2021, Janus Henderson Group held 1,725 positions worth $234B, up 6.7% from $219B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Janus Henderson Group's Q2 2021 filing shows 172 new, 741 increased, 667 reduced and 123 closed positions. Its largest new stake was Centessa Pharmaceuticals: 5,680,933 shares worth $120M. The largest sale was Apple, an estimated $1.14B.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 31% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q2 2021 buy was Centessa Pharmaceuticals: 5,680,933 shares worth $120M.
- Janus Henderson Group added most to United Parcel Service in Q2 2021, an estimated $428M increase.
- Janus Henderson Group's biggest Q2 2021 reduction was Apple, cutting an estimated $1.14B.
- Janus Henderson Group fully exited PRA Health Sciences, Inc. in Q2 2021, selling an estimated $368M.
- Janus Henderson Group's ten largest holdings make up 23% of its $234B portfolio in Q2 2021.
- Janus Henderson Group opened 172 new positions and closed 123 in Q2 2021.
- Janus Henderson Group's portfolio value rose 6.7% quarter-over-quarter to $234B.
Based on Janus Henderson Group's 13F filing for Q2 2021, filed 16 Aug 2021.